WO2001022959A2 - Compositions comprising progesterone or progesterone analogs for the treatment of inflammatory conditions - Google Patents
Compositions comprising progesterone or progesterone analogs for the treatment of inflammatory conditions Download PDFInfo
- Publication number
- WO2001022959A2 WO2001022959A2 PCT/US2000/026501 US0026501W WO0122959A2 WO 2001022959 A2 WO2001022959 A2 WO 2001022959A2 US 0026501 W US0026501 W US 0026501W WO 0122959 A2 WO0122959 A2 WO 0122959A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- progesterone
- disease
- patient
- treatment
- psoriasis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Steroid Compounds (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU79867/00A AU7986700A (en) | 1999-09-28 | 2000-09-27 | Method of treating inflammatory conditions with progesterone or progesterone analogs |
EP00970495A EP1218014A2 (en) | 1999-09-28 | 2000-09-27 | Compositions comprising progesterone or progesterone analogs for the treatment of inflammatory conditions |
MXPA02003285A MXPA02003285A (en) | 1999-09-28 | 2000-09-27 | Compositions comprising progesterone or progesterone analogs for the treatment of inflammatory conditions. |
KR1020027004035A KR20020059416A (en) | 1999-09-28 | 2000-09-27 | Method Of Treating Inflammatory Conditions With Progesterone Or Progesterone Analogs |
JP2001526171A JP2003510277A (en) | 1999-09-28 | 2000-09-27 | Treatment of inflammation with progesterone or progesterone analog |
CA002386404A CA2386404C (en) | 1999-09-28 | 2000-09-27 | Method of treating inflammatory conditions with progesterone or progesterone analogs |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15643499P | 1999-09-28 | 1999-09-28 | |
US60/156,434 | 1999-09-28 | ||
US09/658,867 US6610674B1 (en) | 1999-09-28 | 2000-09-08 | Method of treating inflammatory conditions with progesterone analogs |
US09/658,867 | 2000-09-08 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001022959A2 true WO2001022959A2 (en) | 2001-04-05 |
WO2001022959A3 WO2001022959A3 (en) | 2001-10-04 |
Family
ID=26853177
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/026501 WO2001022959A2 (en) | 1999-09-28 | 2000-09-27 | Compositions comprising progesterone or progesterone analogs for the treatment of inflammatory conditions |
Country Status (8)
Country | Link |
---|---|
US (4) | US6610674B1 (en) |
EP (1) | EP1218014A2 (en) |
JP (1) | JP2003510277A (en) |
KR (1) | KR20020059416A (en) |
AU (1) | AU7986700A (en) |
CA (2) | CA2386404C (en) |
MX (1) | MXPA02003285A (en) |
WO (1) | WO2001022959A2 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003045362A2 (en) * | 2001-11-30 | 2003-06-05 | Solvay Pharmaceuticals Gmbh | Treatment of th1 dominated immunological disease states with non-endogenous gestagen compounds |
US10040816B2 (en) | 2011-05-20 | 2018-08-07 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Antagonists of CB1 receptor |
US10259839B2 (en) | 2012-11-28 | 2019-04-16 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | 3-(4′-substituted)-benzyl-ether derivatives of pregnenolone |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5858981A (en) * | 1993-09-30 | 1999-01-12 | University Of Pennsylvania | Method of inhibiting phagocytosis |
US6887906B1 (en) * | 1997-07-01 | 2005-05-03 | Isispharmaceuticals, Inc. | Compositions and methods for the delivery of oligonucleotides via the alimentary canal |
EP1469009A2 (en) * | 1998-05-21 | 2004-10-20 | Isis Parmaceuticals, Inc. | Compositions and methods for non-parenteral delivery of oligonucleotides |
US20050226878A1 (en) * | 2003-12-02 | 2005-10-13 | 3M Innovative Properties Company | Therapeutic combinations and methods including IRM compounds |
JP2007513165A (en) * | 2003-12-02 | 2007-05-24 | スリーエム イノベイティブ プロパティズ カンパニー | Concomitant drugs containing IRM compounds and methods of treatment |
US7556150B2 (en) * | 2004-06-07 | 2009-07-07 | Duramed Pharmaceuticals, Inc. | Dispenser for progestin used for acute and maintenance treatment of DUB |
US20060211667A1 (en) * | 2005-03-21 | 2006-09-21 | Eric Marchewitz | Use of pregnane steroid derivatives for enhancing physical performance |
JP5544458B2 (en) * | 2005-07-12 | 2014-07-09 | アンピオ ファーマシューティカルズ,インコーポレイテッド | Method of using trilostane III in the manufacture of a pharmaceutical product for treating disease and pharmaceutical product comprising trirostan III |
EP2139491A1 (en) * | 2007-03-16 | 2010-01-06 | Durect Corporation | Use of glucocorticoids for treatment of congestive heart failure |
US8217083B2 (en) * | 2007-06-08 | 2012-07-10 | Aptalis Pharma Canada Inc. | Mesalamine suppository |
US7541384B2 (en) | 2007-06-08 | 2009-06-02 | Axcan Pharma Inc. | Mesalamine suppository |
US8436051B2 (en) * | 2007-06-08 | 2013-05-07 | Aptalis Pharma Canada Inc. | Mesalamine suppository |
CA2744906A1 (en) * | 2007-11-29 | 2009-06-04 | Gregg A. Jackson | Progesterone-containing compositions and devices |
WO2009158384A1 (en) * | 2008-06-27 | 2009-12-30 | The Procter & Gamble Company | Methods and kits for the treatment inhibition, and maintenance of gastrointestinal disorders |
SG2014008171A (en) | 2009-06-22 | 2014-04-28 | Ampio Pharmaceuticals Inc | Method for treatment of diseases |
WO2010151531A1 (en) * | 2009-06-22 | 2010-12-29 | Dmi Acquistion Corp. | Methods and products for treatment of diseases |
WO2011096438A1 (en) * | 2010-02-03 | 2011-08-11 | 国立大学法人 東京大学 | Method and pharmaceutical composition for treatment of intestinal disease |
ES2885523T3 (en) | 2011-11-23 | 2021-12-14 | Therapeuticsmd Inc | Natural combination hormone replacement formulations and therapies |
US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US9351979B2 (en) | 2012-12-19 | 2016-05-31 | Ampio Pharmaceuticals, Inc. | Methods of treatment of diseases |
US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
EP2774951B1 (en) | 2013-03-06 | 2016-02-03 | Basf Se | Polymer blends containing long-chain polycondensates |
HUE034886T2 (en) | 2013-03-15 | 2018-03-28 | Glia Llc | Cranial delivery of pharmaceuticals |
AU2015264003A1 (en) | 2014-05-22 | 2016-11-17 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
WO2016018993A1 (en) | 2014-07-29 | 2016-02-04 | Therapeuticsmd, Inc. | Transdermal cream |
US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
WO2017173071A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
EP3930735A1 (en) * | 2019-02-26 | 2022-01-05 | The Regents of the University of Colorado, a body corporate | Method and composition for treating gastrointestinal inflammatory disorders |
US11633405B2 (en) | 2020-02-07 | 2023-04-25 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical formulations |
CN111617107A (en) * | 2020-04-10 | 2020-09-04 | 王全栋 | Pharmaceutical composition for treating colitis |
CN113559107B (en) * | 2020-04-28 | 2023-01-06 | 深圳埃格林医药有限公司 | Application of progestogen in preparing medicine for inhibiting cell factor storm |
EP4035663A4 (en) * | 2020-12-17 | 2022-12-07 | Shenzhen Evergreen Therapeutics Co., Ltd. | Use of progestin in treating cytokine release syndrome |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB994547A (en) * | 1963-01-17 | 1965-06-10 | Farmaceutici Italia | Steroids |
DE2240187A1 (en) * | 1972-08-16 | 1974-02-21 | Jereb Franz Dr Albin | Vitamin/hormone ointment - esp for skin disorders |
US4439432A (en) * | 1982-03-22 | 1984-03-27 | Peat Raymond F | Treatment of progesterone deficiency and related conditions with a stable composition of progesterone and tocopherols |
US5612051A (en) * | 1995-11-17 | 1997-03-18 | Yue; Samuel K. | Method of treating involuntary muscle dysfunction with relaxin hormone |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4902681A (en) * | 1987-08-27 | 1990-02-20 | University Of Pennsylvania | Inhibition of immune clearance using progesterone analogues |
US5156850A (en) * | 1990-08-31 | 1992-10-20 | Alza Corporation | Dosage form for time-varying patterns of drug delivery |
GB9612993D0 (en) * | 1996-06-20 | 1996-08-21 | Gyrus Medical Ltd | Electrosurgical instrument |
WO1999058126A1 (en) * | 1998-05-11 | 1999-11-18 | The Endowment For Research In Human Biology, Inc. | Use of neomycin for treating angiogenesis-related diseases |
-
2000
- 2000-09-08 US US09/658,867 patent/US6610674B1/en not_active Expired - Fee Related
- 2000-09-27 EP EP00970495A patent/EP1218014A2/en not_active Withdrawn
- 2000-09-27 AU AU79867/00A patent/AU7986700A/en not_active Abandoned
- 2000-09-27 WO PCT/US2000/026501 patent/WO2001022959A2/en not_active Application Discontinuation
- 2000-09-27 CA CA002386404A patent/CA2386404C/en not_active Expired - Fee Related
- 2000-09-27 KR KR1020027004035A patent/KR20020059416A/en not_active Application Discontinuation
- 2000-09-27 CA CA002657208A patent/CA2657208A1/en not_active Abandoned
- 2000-09-27 JP JP2001526171A patent/JP2003510277A/en active Pending
- 2000-09-27 MX MXPA02003285A patent/MXPA02003285A/en unknown
-
2003
- 2003-06-24 US US10/601,756 patent/US20040038954A1/en not_active Abandoned
-
2005
- 2005-03-09 US US11/074,938 patent/US20050203073A1/en not_active Abandoned
-
2007
- 2007-08-14 US US11/889,572 patent/US20080076744A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB994547A (en) * | 1963-01-17 | 1965-06-10 | Farmaceutici Italia | Steroids |
DE2240187A1 (en) * | 1972-08-16 | 1974-02-21 | Jereb Franz Dr Albin | Vitamin/hormone ointment - esp for skin disorders |
US4439432A (en) * | 1982-03-22 | 1984-03-27 | Peat Raymond F | Treatment of progesterone deficiency and related conditions with a stable composition of progesterone and tocopherols |
US5612051A (en) * | 1995-11-17 | 1997-03-18 | Yue; Samuel K. | Method of treating involuntary muscle dysfunction with relaxin hormone |
Non-Patent Citations (6)
Title |
---|
CULLINS VANESSA E: "Noncontraceptive benefits and therapeutic uses of depot medroxyprogesterone acetate." JOURNAL OF REPRODUCTIVE MEDICINE, vol. 41, no. 5 SUPPL., 1996, pages 428-433, XP000992806 ISSN: 0024-7758 cited in the application * |
ELIAKIM RAMI ET AL: "Estrogen, progesterone and the gastrointestinal tract." JOURNAL OF REPRODUCTIVE MEDICINE, vol. 45, no. 10, October 2000 (2000-10), pages 781-788, XP000992768 ISSN: 0024-7758 * |
HANEY A F ET AL: "REDUCTION OF THE INTRAPERITONEAL INFLAMMATION ASSOCIATED WITH ENDOMETRIOSIS BY TREATMENT WITH MEDROXYPROGESTERONE ACETATE" AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, vol. 159, no. 2, 1988, pages 450-454, XP000992737 ISSN: 0002-9378 * |
MURCH S H ET AL: "MEDICAL MANAGEMENT OF CHRONIC INFLAMMATORY BOWEL DISEASE" BAILLIERES CLINICAL GASTROENTEROLOGY,GB,BAILLIERES TINDALL, LONDON, vol. 8, no. 1, March 1994 (1994-03), pages 133-148, XP000901064 ISSN: 0950-3528 * |
NAKAGAWA H ET AL: "ANTI INFLAMMATORY ACTION OF PROGESTERONE AND ITS POSSIBLE MODE OF ACTION IN RATS" BIOCHEMICAL PHARMACOLOGY, vol. 30, no. 6, 1981, pages 639-644, XP000992862 ISSN: 0006-2952 * |
REYNOLDS P D ET AL: "PHARMACOTHERAPY OF INFLAMMATORY BOWEL DISEASE" DIGESTIVE DISEASES AND SCIENCES,US,PLENUM PUBLISHING CO, vol. 11, no. 6, 1 November 1993 (1993-11-01), pages 334-342, XP000612355 ISSN: 0163-2116 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003045362A2 (en) * | 2001-11-30 | 2003-06-05 | Solvay Pharmaceuticals Gmbh | Treatment of th1 dominated immunological disease states with non-endogenous gestagen compounds |
WO2003045362A3 (en) * | 2001-11-30 | 2003-12-18 | Solvay Pharm Gmbh | Treatment of th1 dominated immunological disease states with non-endogenous gestagen compounds |
US10040816B2 (en) | 2011-05-20 | 2018-08-07 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Antagonists of CB1 receptor |
US10150793B2 (en) | 2011-05-20 | 2018-12-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antagonists of CB1 receptor |
US10259839B2 (en) | 2012-11-28 | 2019-04-16 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | 3-(4′-substituted)-benzyl-ether derivatives of pregnenolone |
Also Published As
Publication number | Publication date |
---|---|
US6610674B1 (en) | 2003-08-26 |
CA2657208A1 (en) | 2001-04-05 |
CA2386404C (en) | 2009-05-12 |
WO2001022959A3 (en) | 2001-10-04 |
KR20020059416A (en) | 2002-07-12 |
MXPA02003285A (en) | 2002-09-02 |
JP2003510277A (en) | 2003-03-18 |
AU7986700A (en) | 2001-04-30 |
US20080076744A1 (en) | 2008-03-27 |
US20040038954A1 (en) | 2004-02-26 |
US20050203073A1 (en) | 2005-09-15 |
EP1218014A2 (en) | 2002-07-03 |
CA2386404A1 (en) | 2001-04-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2386404C (en) | Method of treating inflammatory conditions with progesterone or progesterone analogs | |
Regueiro et al. | Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease | |
Hanauer | Medical therapy for ulcerative colitis 2004 | |
Evans et al. | Treatment of ulcerative colitis with an engineered human anti‐TNFα antibody CDP571 | |
Thongprasom et al. | Relative efficacy of fluocinolone acetonide compared with triamcinolone acetonide in treatment of oral lichen planus | |
Armuzzi et al. | Infliximab in the treatment of steroid-dependent ulcerative colitis | |
Buchanec et al. | Incidence of renal complications in Schönlein—Henoch purpura syndrome in dependence of an early administration of steriods | |
JPWO2004082715A1 (en) | Concomitant medications as therapeutic agents for inflammatory bowel disease | |
WO2005023193A2 (en) | Methods of treating endometriosis | |
Owen et al. | Methotrexate in Reiter's disease. | |
Kim et al. | The use of etanercept in the treatment of peristomal pyoderma gangrenosum | |
WO1997016185A2 (en) | A pharmaceutical composition for the treatment of autoimmune diseases | |
Panaccione | Infliximab for the treatment of Crohn's disease: review and indications for clinical use in Canada | |
CA2274943A1 (en) | Compositions for the treatment and prevention of inflammatory diseases of the gastrointestinal tract and methods and uses thereof | |
EP1830857A2 (en) | Treatment of graft-versus-host disease and leukemia with beclomethasone dipropionate and prednisone | |
Przybylska et al. | Lichen sclerosus as a clinical problem | |
JP5371189B2 (en) | Use of ciclesonide for the treatment of inflammatory bowel disease | |
JP4233766B2 (en) | Use of dienogest at high dosages | |
Nagaraja | To Study Efficacy of Mifepristone with Foley’s Catheter and Misoprostol in Second Trimester Termination of Pregnancy | |
Mazzone et al. | Pyoderma gangrenosum complicating ulcerative colitis: An alternative treatment with iloprost | |
Iwama et al. | Anal complication in Behçet's syndrome | |
RU2215546C1 (en) | Method for treating inspecific ulcerous colitis | |
Dubois | Paramethasone in the Treatment of Systemic Lupus Erythematosus: Analysis of Results in 51 Patients with Emphasis on Single Daily Oral Doses | |
RU2149005C1 (en) | Method for treating viral and chlamydia infections | |
Graham et al. | IL-1β downregulates collagen and augments collagenase expression in human intestinal smooth muscle (HISM) cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2386404 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2001 526171 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020027004035 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2002/003285 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000970495 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2000970495 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020027004035 Country of ref document: KR |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000970495 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |